What is Advanced BioMatrix?
Advanced BioMatrix operates at the intersection of material science and regenerative medicine, specializing in the development of high-performance collagen-based products and advanced bioprinting solutions. With a legacy spanning over 25 years, the organization provides essential bioinks, hydrogels, and extracellular matrix components that serve as the foundation for modern cell culture and tissue engineering. By bridging the gap between laboratory research and clinical application, the company enables researchers to push the boundaries of therapeutic development. Their commitment to quality and precision manufacturing has established them as a trusted partner for organizations seeking to innovate in the fields of drug discovery and life-saving medical technologies.
How much funding has Advanced BioMatrix raised?
Advanced BioMatrix has raised a total of $93K across 1 funding round:
Debt
$93K
Debt (2021): $93K with participation from PPP
Key Investors in Advanced BioMatrix
PPP
Public-Private Partnership
What's next for Advanced BioMatrix?
With the recent infusion of capital, Advanced BioMatrix is poised to enter a new phase of operational maturity. The strategic focus will likely shift toward expanding its product portfolio to meet the increasing demand for sophisticated 3D bioprinting materials. As the company transitions through its current growth stage, management is expected to prioritize the optimization of its supply chain and the enhancement of its R&D infrastructure. This trajectory suggests a concerted effort to solidify market leadership in the tissue engineering sector, potentially paving the way for future strategic partnerships or further scaling of its commercial footprint in the life sciences industry.
See full Advanced BioMatrix company page
